Bioscience ClubhouseCT Presents: The Story of Biorez featuring Kevin Rocco, CEO

We are a clinical stage regenerative medicine company.

Dedicated to developing off-the-shelf, tissue-engineered scaffold implants that are fully bioresorbable and remodel into functional tissue. Our regenerative approach enables the body to heal itself without the pain and risks associated with traditional surgical implants, such as autograft or allograft.

Our product is implanted using standard surgical techniques to stabilize the knee. Stem cells then wick into the porous scaffold from within the bone marrow to fully populate the device. The cells follow our proprietary structure to reform a tissue bridge connecting the femur and tibia. Over time, and as the patient undergoes physical rehabilitation, the cells receive mechanical signaling to develop mature extracellular matrix, resembling native ligament tissue. The polymer gradually resorbs, transferring all load to the patient’s new tissue.

Kevin Rocco, Chief Executive Officer
Kevin joined Biorez in February 2014 as the lead engineer, and in November 2016 was promoted to CEO and joined the Board of Directors. As CEO, Kevin has led a $1.5 million fundraising effort, rebranded the company, grown the Biorez team, and filed a new patent for Biorez’s lead ACL technology in March 2017. Prior to joining Biorez, Kevin studied tissue engineering at Yale University, where he coauthored 17 publications in the field and was a part of the research team with the first US clinical study of a bioresorbable vascular graft in human. Kevin began his career as an engineer in new technology development at Covidien (acquired by Medtronic) where he investigated a novel bioresorbable hernia mesh device. He holds a B.S. and M.S. in Biomedical Engineering from The University of Connecticut and Yale University, respectively.